Alkermes plc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Alkermes plc. (ALKS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $31.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-28
- Alkermes plc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $31.34M, a 23.17% increase year-over-year.
- Alkermes plc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $34.95M, a 52.72% increase year-over-year.
- Alkermes plc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $25.43M, a 15.23% increase year-over-year.
- Alkermes plc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $25.44M, a 23.47% increase year-over-year.
- Alkermes plc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $100.41M, a 4.13% increase from fiscal 2024.
- Alkermes plc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $96.42M, a 4.41% decline from fiscal 2023.
- Alkermes plc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $100.87M, a 5.98% increase from fiscal 2022.
- Alkermes plc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $95.18M, a 8.90% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.34M 10-Q · filed 2026-07-28 | $66.28M derived: sum of 2 quarters · filed 2026-07-28 | ||
| 2026-03-31 | $34.95M 10-Q · filed 2026-07-28 | |||
| 2025-12-31 | $100.41M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $25.43M 10-Q · filed 2025-10-28 | $50.87M derived: sum of 2 quarters · filed 2026-07-28 | $73.76M derived: sum of 3 quarters · filed 2026-07-28 | |
| 2025-06-30 | $25.44M 10-Q · filed 2026-07-28 | $48.33M derived: sum of 2 quarters · filed 2026-07-28 | ||
| 2025-03-31 | $22.88M 10-Q · filed 2026-07-28 | |||
| 2024-12-31 | $96.42M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $22.07M 10-Q · filed 2025-10-28 | $42.68M derived: sum of 2 quarters · filed 2025-10-28 | $75.54M derived: sum of 3 quarters · filed 2025-10-28 | |
| 2024-06-30 | $20.61M 10-Q · filed 2025-10-28 | $53.47M derived: sum of 2 quarters · filed 2025-10-28 | ||
| 2024-03-31 | $32.86M 10-Q · filed 2025-10-28 | |||
| 2023-12-31 | $100.87M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $23.71M 10-Q · filed 2024-10-24 | $52.23M derived: sum of 2 quarters · filed 2024-10-24 | $75.00M derived: sum of 3 quarters · filed 2024-10-24 | |
| 2023-06-30 | $28.52M 10-Q · filed 2024-10-24 | $51.30M derived: sum of 2 quarters · filed 2024-10-24 | ||
| 2023-03-31 | $22.78M 10-Q · filed 2024-10-24 | |||
| 2022-12-31 | $95.18M 10-K · filed 2025-02-12 | |||
| 2022-09-30 | $26.32M 10-Q · filed 2023-10-25 | $49.96M derived: sum of 2 quarters · filed 2023-10-25 | $68.45M derived: sum of 3 quarters · filed 2023-10-25 | |
| 2022-06-30 | $23.64M 10-Q · filed 2023-10-25 | $42.13M derived: sum of 2 quarters · filed 2023-10-25 | ||
| 2022-03-31 | $18.49M 10-Q · filed 2023-10-25 | |||
| 2021-12-31 | $87.40M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | $25.70M 10-Q · filed 2022-11-02 | $52.62M derived: sum of 2 quarters · filed 2022-11-02 | $68.17M derived: sum of 3 quarters · filed 2022-11-02 | |
| 2021-06-30 | $26.92M 10-Q · filed 2022-11-02 | $42.47M derived: sum of 2 quarters · filed 2022-11-02 | ||
| 2021-03-31 | $15.55M 10-Q · filed 2022-11-02 | |||
| 2020-12-31 | $91.26M 10-K · filed 2023-02-16 | |||
| 2020-09-30 | $22.71M 10-Q · filed 2021-10-27 | $45.84M derived: sum of 2 quarters · filed 2021-10-27 | $65.97M derived: sum of 3 quarters · filed 2021-10-27 | |
| 2020-06-30 | $23.14M 10-Q · filed 2021-10-27 | $43.26M derived: sum of 2 quarters · filed 2021-10-27 | ||
| 2020-03-31 | $20.13M 10-Q · filed 2021-10-27 | |||
| 2019-12-31 | $99.70M 10-K · filed 2022-02-16 | |||
| 2019-09-30 | $26.30M 10-Q · filed 2020-10-29 | $54.56M derived: sum of 2 quarters · filed 2020-10-29 | $79.37M derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-30 | $28.26M 10-Q · filed 2020-10-29 | $53.07M derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-31 | $24.81M 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | $107.71M 10-K · filed 2021-02-11 | |||
| 2018-09-30 | $25.41M 10-Q · filed 2019-10-23 | $56.36M derived: sum of 2 quarters · filed 2019-10-23 | $76.54M derived: sum of 3 quarters · filed 2019-10-23 | |
| 2018-06-30 | $30.95M 10-Q · filed 2019-10-23 | $51.12M derived: sum of 2 quarters · filed 2019-10-23 | ||
| 2018-03-31 | $20.18M 10-Q · filed 2019-10-23 | |||
| 2017-12-31 | $83.18M 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $94.46M 10-K · filed 2019-02-15 | |||
| 2015-12-31 | $97.62M 10-K · filed 2018-02-16 | |||
| 2014-12-31 | $59.91M 10-K · filed 2017-02-17 | |||
| 2013-12-31 | $33.27M 10-K · filed 2016-02-25 | |||
| 2013-03-31 | $34.93M 10-K · filed 2015-02-24 | |||
| 2012-03-31 | $6.80M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $15.98M derived: sum of 2 quarters · filed 2014-02-27 | $28.61M 10-KT · filed 2014-02-27 | |
| 2011-12-31 | $9.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | $21.81M 10-Q · filed 2012-02-02 | ||
| 2011-09-30 | $12.64M 10-Q · filed 2011-11-03 | |||
| 2011-03-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $10.47M derived: sum of 2 quarters · filed 2013-05-23 | $19.82M 10-K · filed 2013-05-23 | |
| 2010-12-31 | $5.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | $15.13M 10-Q · filed 2012-02-02 | ||
| 2010-09-30 | $9.35M 10-Q · filed 2011-11-03 | |||
| 2010-03-31 | $14.11M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |